Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Analytical aspects of molecular Alzheimer's disease biomarkers.

Andreasson U, Vanmechelen E, Shaw LM, Zetterberg H, Vanderstichele H.

Biomark Med. 2012 Aug;6(4):377-89. doi: 10.2217/bmm.12.44. Review.

PMID:
22917140
2.

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.

Mattsson N, Zegers I, Andreasson U, Bjerke M, Blankenstein MA, Bowser R, Carrillo MC, Gobom J, Heath T, Jenkins R, Jeromin A, Kaplow J, Kidd D, Laterza OF, Lockhart A, Lunn MP, Martone RL, Mills K, Pannee J, Ratcliffe M, Shaw LM, Simon AJ, Soares H, Teunissen CE, Verbeek MM, Umek RM, Vanderstichele H, Zetterberg H, Blennow K, Portelius E.

Biomark Med. 2012 Aug;6(4):409-17. doi: 10.2217/bmm.12.39. Review.

PMID:
22917143
3.

Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.

Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin JJ, Engelborghs S.

J Alzheimers Dis. 2013;33(1):117-31. doi: 10.3233/JAD-2012-121246.

PMID:
22936010
4.

Clinical use of cerebrospinal fluid biomarkers in Alzheimer's disease.

Zetterberg H, Lunn MP, Herukka SK.

Biomark Med. 2012 Aug;6(4):371-6. doi: 10.2217/bmm.12.47.

PMID:
22917139
5.

Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers.

Mattsson N, Andreasson U, Carrillo MC, Persson S, Shaw LM, Zegers I, Zetterberg H, Blennow K.

Biomark Med. 2012 Aug;6(4):401-7. doi: 10.2217/bmm.12.41. Review.

PMID:
22917142
6.

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.

Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, Teunissen C, Wouters D, Blennow K.

Alzheimers Dement. 2012 Jan;8(1):65-73. doi: 10.1016/j.jalz.2011.07.004. Epub 2011 Nov 2. Review.

PMID:
22047631
7.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
8.

Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update.

del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, Kapaki E, Kruse N, Le Bastard N, Lehmann S, Molinuevo JL, Parnetti L, Perret-Liaudet A, Sáez-Valero J, Saka E, Urbani A, Vanmechelen E, Verbeek M, Visser PJ, Teunissen C.

Biomark Med. 2012 Aug;6(4):419-30. doi: 10.2217/bmm.12.46. Review.

PMID:
22917144
9.

Cerebrospinal fluid biomarkers for Alzheimer's disease: more to come?

Zetterberg H, Blennow K.

J Alzheimers Dis. 2013;33 Suppl 1:S361-9. Review.

PMID:
22710917
10.

[Biomarkers for Alzheimer's disease: after Alzheimer's disease neuroimaging initiative studies].

Shoji M.

Brain Nerve. 2012 May;64(5):497-504. Review. Japanese.

PMID:
22570063
11.

[A new approach to the Alzheimer's disease diagnosis with biomarkers: description of the AD-CSF-Index].

Molinuevo JL, Gispert JD, Pujol J, Rojas S, Lladó A, Balasa M, Antonell A, Sánchez-Valle R, Rami L.

Rev Neurol. 2012 May 1;54(9):513-22. Spanish.

12.

Comparison of immunosorbent assays for the quantification of biomarkers for Alzheimer's disease in human cerebrospinal fluid.

Schipke CG, Prokop S, Heppner FL, Heuser I, Peters O.

Dement Geriatr Cogn Disord. 2011;31(2):139-45. doi: 10.1159/000322588. Epub 2011 Feb 8.

PMID:
21304219
13.

Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease.

Wang LS, Leung YY, Chang SK, Leight S, Knapik-Czajka M, Baek Y, Shaw LM, Lee VM, Trojanowski JQ, Clark CM.

J Alzheimers Dis. 2012;31(2):439-45. doi: 10.3233/JAD-2012-120082.

14.

Cerebrospinal fluid biomarkers for Alzheimer's disease.

Blennow K, Zetterberg H.

J Alzheimers Dis. 2009;18(2):413-7. doi: 10.3233/JAD-2009-1177. Review.

PMID:
19661632
15.

Cerebrospinal fluid proteins in the diagnosis of Alzheimer's disease.

Papaliagkas VT, Tsolaki M, Anogianakis G.

Recent Pat CNS Drug Discov. 2010 Jun;5(2):172-8. Review.

PMID:
20408808
16.

Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.

Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L.

J Alzheimers Dis. 2010;21(2):471-8. doi: 10.3233/JAD-2010-091594.

PMID:
20555147
17.

Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease.

Ishiguro K, Ohno H, Arai H, Yamaguchi H, Urakami K, Park JM, Sato K, Kohno H, Imahori K.

Neurosci Lett. 1999 Jul 30;270(2):91-4.

PMID:
10462105
18.

Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall.

Mattsson N, Blennow K, Zetterberg H.

Clin Chem Lab Med. 2010 May;48(5):603-7. doi: 10.1515/CCLM.2010.131. Review.

PMID:
20201744
19.

Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges.

Bartlett JW, Frost C, Mattsson N, Skillbäck T, Blennow K, Zetterberg H, Schott JM.

Biomark Med. 2012 Aug;6(4):391-400. doi: 10.2217/bmm.12.49. Review.

PMID:
22917141
20.

PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers.

Balasa M, Vidal-Piñeiro D, Lladó A, Antonell A, Bosch B, Castellanos F, Bargalló N, Bartres-Faz D, Molinuevo JL, Sánchez-Valle R.

J Alzheimers Dis. 2012;30(3):605-16. doi: 10.3233/JAD-2012-111949.

PMID:
22426017

Supplemental Content

Support Center